Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Glucosamine, a go-to supplement for joint pain, may be speeding up Alzheimer's progression. A University of Florida study found that people with mild cognitive impairment who took glucosamine were 25% more likely to develop dementia. Lab experiments in mice and human brain tissue point to an overactive sugar-tagging process in the Alzheimer's brain as a possible culprit — though clinical trials are still needed.
Glucosamine — the over-the-counter supplement millions of older adults take for joint health — may be doing their brains no favors. Researchers at the University of Florida analyzed health records from over 4,600 patients and found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment (MCI) progressing to full dementia. Among those already diagnosed with Alzheimer's and related dementias, glucosamine use was also tied to a 25% higher mortality risk.
The team didn't stop at health records. Experiments in mouse models and human Alzheimer's brain tissue revealed a potential biological explanation: glucosamine appears to amplify an already-overactive "sugar-tagging" process in the Alzheimer's brain, where sugar structures are excessively attached to proteins, disrupting their normal function. When researchers chemically suppressed this process in mice, memory performance improved.
By the Numbers:
Why it matters: Glucosamine is widely available without a prescription and heavily used by the older adult population — the same group most at risk for cognitive decline. While this study shows association, not causation, the findings are significant enough that clinicians may want to discuss glucosamine use with cognitively vulnerable patients. A controlled clinical trial is the critical next step.
